TP53 and cancer: Risk adjusted cancer surveillance or screening typically based on clinical assessment, imaging and biochemical screening, which has shown clinical benefit for patients with hereditary breast and ovarian cancer, Lynch syndrome and TP53-associated Li Fraumeni syndrome, and gains increasing relevance for long-term survivors due to improved therapies.